The companion animal infectious disease diagnostics market — covering diagnostic tests for dogs, cats, and other pets to detect viral, bacterial, parasitic and other infections — is poised for robust growth over the next decade. As pet ownership rises globally and pet humanization grows, demand for accurate, rapid, and reliable diagnostic tools in veterinary clinics and reference laboratories is accelerating. Increasing awareness about pet health, preventive care, routine screening, and early disease detection are driving the use of advanced diagnostics rather than solely clinical observation. Additionally, technological advances in immunodiagnostics and molecular diagnostics are expanding the diagnostic capabilities and improving speed, precision, and multiplexing — supporting broader adoption among veterinarians and pet owners.
Quick Stats (2025–2035)
Market Value 2025: USD 1.4 billion
Forecast Market Value 2035: USD 2.8 billion
Absolute Growth (2025–2035): USD 1.5 billion
Forecast CAGR (2025–2035): ~7.2%
Leading Product Type (2025): Consumables, Reagents & Kits (~64.1% share)
Leading Technology (2025): Immunodiagnostics (~49.7% share)
To access the complete data tables and in-depth insights, request a Discount On The Report here: https://www.factmr.com/connectus/sample?flag=S&rep_id=12394
Key Market Drivers
1. Rising Pet Ownership & Pet Humanization
Increasing number of households owning pets — especially dogs and cats — drives demand for regular health check-ups and diagnostics.
Owners view pets as family members, thus prioritizing preventive care, early disease detection, and overall wellness — prompting higher uptake of diagnostic tests even for routine screening.
Growing pet-care spending, including diagnostics, vaccines, and wellness screening, supports long-term growth.
2. Growing Awareness of Infectious & Zoonotic Diseases
Greater awareness of zoonotic risks and pet infectious diseases (viral, bacterial, parasitic) encourages diagnostic use for early detection, both for pet health and public health safety.
Preventive screening protocols in veterinary clinics — especially for common or regionally prevalent diseases — are becoming standard, increasing routine diagnostic volume.
3. Demand for Rapid & Accurate Diagnostics in Clinics
Immunodiagnostics (rapid tests, ELISA-based assays, lateral-flow assays) enable quick, point-of-care diagnosis — critical for effective treatment initiation and owner convenience.
Veterinarians prefer reliable, easy-to-use tests that deliver quick results during clinic visits, avoiding long lab turnaround times.
4. Technological Advances & Molecular Diagnostics Adoption
Molecular diagnostics (e.g., PCR) offer high sensitivity and specificity — useful for confirming pathogens, strain typing, and detecting difficult-to-diagnose infections.
Broader adoption of molecular testing in reference labs and specialized veterinary facilities supports market growth, especially for complex or multiplex testing needs.
5. Expansion of Veterinary Infrastructure & Diagnostic Capacity
Growth in veterinary clinics, animal hospitals, diagnostic labs, and veterinary reference centers increases access to diagnostics, even in previously underserved regions.
Rising demand for comprehensive pet health services (vaccination, screening, wellness plans) encourages clinics to adopt in-house diagnostic capabilities or partner with labs.
Market Structure & Segment Insights
By Product / Service Type
Consumables, Reagents & Kits: Dominant segment — used for routine screenings, vaccinations, disease surveillance, and frequent testing cycles. High recurring demand supports consistent revenue.
Equipment & Instruments: Important for reference labs and advanced diagnostic centers — molecular testing platforms, immunoassay analyzers, and multiplex-testing devices.
Testing Services: Provided by specialized labs for clinics lacking in-house capabilities — especially valuable for complex molecular tests or multiplex panels.
By Technology
Immunodiagnostics: Leading technology — preferred for rapid, point-of-care, cost-effective diagnostics, including broad screening for bacterial, viral, parasitic infections.
Molecular Diagnostics: Growing share — used for confirmatory testing, pathogen identification, strain typing, and multiplex testing where precision and sensitivity are critical.
Multiplex & Panel Testing: Emerging trend — enables simultaneous pathogen screening, saving time and improving diagnostic coverage.
By Animal Type & Disease Indication
Dogs (Canine): Largest share — high pet population, frequent vet visits, routine wellness screening, and preventive care culture drive diagnostics demand.
Cats (Feline): Also significant — as cat ownership rises, demand for feline-specific diagnostics (viral, respiratory, parasitic) increases.
Common Indications: Bacterial infections (skin, urinary, respiratory), viral diseases, parasitic infections — bacterial diagnostics currently lead, but viral and parasitic diagnostics are gaining share.
By End-Use / User Segment
Veterinary Hospitals & Clinics: Largest end-user segment — in-house testing allows same-visit diagnosis and treatment.
Veterinary Reference Laboratories: Handle complex, multiplex, or confirmatory testing, especially molecular diagnostics; preferred for high-sensitivity or rare-disease detection.
Mobile / Point-of-Care Testing Services: Growing concept — diagnostic service providers catering to smaller clinics or remote areas with portable kits and sample transport.
Challenges & Market Restraints
Cost Sensitivity Among Pet Owners: Diagnostic tests (especially molecular or multiplex panels) can be costly; some owners may avoid non-urgent testing due to price.
Lack of Veterinary Infrastructure in Emerging Markets: In many regions, limited lab facilities, lack of trained personnel, or low veterinary penetration hamper diagnostic adoption.
Awareness & Adoption Gaps: Not all pet owners or clinics prioritize regular infectious-disease screening — especially where preventive care culture is nascent.
Regulatory & Quality Assurance Challenges: Ensuring test accuracy, standardization, and regulatory compliance across regions can be complex — may limit adoption of newer molecular methods in some markets.
Technical Complexity: Molecular diagnostics require specialized equipment, trained staff, and strict sample handling — a barrier for small clinics.
Opportunities & Strategic Directions
1. Preventive Health & Wellness Screening Programs
Launching regular wellness-screen packages (annual check-ups, screening panels) for pets can boost recurring diagnostic demand.
Pet insurance adoption and preventive-care plans can encourage owners to invest in diagnostics beyond treatment-only visits.
2. Affordable, Point-of-Care & Multiplex Diagnostic Solutions
Development of low-cost, easy-to-use kits for rapid immunodiagnostic screening — especially in price-sensitive or emerging markets.
Multiplex panels for simultaneous detection of multiple pathogens — cost-efficient and appealing to clinics and owners for broad coverage.
3. Expansion of Molecular & Reference-Lab Services
Building reference lab networks and offering remote sample collection drives access to high-precision molecular diagnostics beyond major urban centers.
Offering confirmatory testing, specialized panels, and antimicrobial resistance profiling enhances value and appeals to advanced clinics.
4. Integration with Tele-Veterinary Services & Remote Diagnostics
With growth in telemedicine for pets, remote testing and at-home sample collection kits — sending results digitally — can expand reach, especially in rural or underserved areas.
Combining diagnostics with tele-consultations increases convenience and broadens market potential.
5. Focus on Under-Served Regions & Emerging Markets
Growing pet ownership in emerging economies presents a major opportunity — affordable diagnostic solutions can capture early demand before saturation.
Educating pet owners about preventive care and zoonotic risks can drive diagnostic adoption.
Outlook
The companion animal infectious disease diagnostics market is expected to nearly double over the next decade — growing from USD 1.4 billion in 2025 to USD 2.8 billion by 2035, at a forecast CAGR of ~7.2%. Demand will be driven by rising pet ownership, increasing preventive-care awareness, veterinary infrastructure expansion, and continued technological innovation (immunodiagnostics, molecular diagnostics, multiplex testing).
As diagnostics become more accessible, affordable, and integrated into routine pet-health practices, the market will further broaden beyond major economies into emerging regions. Companies offering a mix of cost-effective kits, advanced molecular services, multiplex panels, and flexible service models (in-clinic testing, reference lab services, tele-vet integration) will likely lead this growth.
Overall, companion-animal infectious-disease diagnostics is evolving from niche, reactive testing toward a standardized, preventive, and routine component of pet healthcare — aligned with rising pet humanization, regulatory awareness, and demand for high-quality veterinary care worldwide.
Have specific requirements or need assistance on report pricing or have a limited budget? Please contact [email protected]
About Fact.MR:
Fact.MR is a global market research and consulting firm, trusted by Fortune 500 companies and emerging businesses for reliable insights and strategic intelligence. With a presence across the U.S., UK, India, and Dubai, we deliver data-driven research and tailored consulting solutions across 30+ industries and 1,000+ markets. Backed by deep expertise and advanced analytics, Fact.MR helps organizations uncover opportunities, reduce risks, and make informed decisions for sustainable growth.
